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Objective: This study was undertaken to determine whether epilepsy and antiepilep-
tic drugs (including enzyme- inducing and non- enzyme- inducing drugs) are associated 
with major cardiovascular events using population- level, routinely collected data.
Methods: Using anonymized, routinely collected, health care data in Wales, UK, 
we performed a retrospective matched cohort study (2003– 2017) of adults with epi-
lepsy prescribed an antiepileptic drug. Controls were matched with replacement on 
age, gender, deprivation quintile, and year of entry into the study. Participants were 
followed to the end of the study for the occurrence of a major cardiovascular event, 
and survival models were constructed to compare the time to a major cardiovascular 
event (cardiac arrest, myocardial infarction, stroke, ischemic heart disease, clinically 
significant arrhythmia, thromboembolism, onset of heart failure, or a cardiovascular 
death) for individuals in the case group versus the control group.
Results: There were 10 241 cases (mean age = 49.6 years, 52.2% male, mean follow-
 up = 6.1 years) matched to 35 145 controls. A total of 3180 (31.1%) cases received 
enzyme- inducing antiepileptic drugs, and 7061 (68.9%) received non- enzyme- inducing 
antiepileptic drugs. Cases had an increased risk of experiencing a major cardiovascu-
lar event compared to controls (adjusted hazard ratio = 1.58, 95% confidence interval 
[CI] = 1.51– 1.63, p < .001). There was no notable difference in major cardiovascu-
lar events between those treated with enzyme- inducing antiepileptic drugs and those 
treated with non- enzyme- inducing antiepileptic drugs (adjusted hazard ratio = .95, 
95% CI = .86– 1.05, p = .300).
Significance: Individuals with epilepsy prescribed antiepileptic drugs are at an in-
creased risk of major cardiovascular events compared with population controls. Being 
prescribed an enzyme- inducing antiepileptic drug is not associated with a greater risk 
of a major cardiovascular event compared to treatment with other antiepileptic drugs. 
Our data emphasize the importance of cardiovascular risk management in the clinical 
care of people with epilepsy.
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1 |  INTRODUCTION
Epilepsy is a common neurological condition, and individu-
als with epilepsy have higher mortality rates than the general 
population.1,2 Although part of this increased risk may be 
explained by comorbid conditions or lifestyle factors, car-
diovascular events associated with epilepsy or antiepileptic 
drugs (AEDs) may also contribute.
For most people with epilepsy, AEDs are the mainstay 
of treatment. Previous studies have suggested a link between 
AEDs and an increased risk of cardiovascular events, such as 
stroke, myocardial infarction, and arrhythmia.3– 5 AEDs can 
be grouped into enzyme- inducing AEDs (EIAEDs; e.g., phe-
nytoin, phenobarbital, and carbamazepine) and non- enzyme- 
inducing AEDs (NEIAEDs), based on their action on the 
hepatic enzyme system.6 Older AEDs, which are mainly en-
zyme inducers, may be associated with more adverse effects 
and may alter metabolic pathways related to vascular risk.7– 9 
EIAEDs are associated with elevated levels of total choles-
terol and low- density lipoprotein cholesterol due to effects on 
enzymes involved in cholesterol synthesis.7– 13 Other vascular 
risk markers may be affected by AEDs, including homocys-
teine and C- reactive protein.14,15
Despite the evidence linking AEDs to lipid abnormalities, 
there is a lack of evidence of their effect on cardiovascular 
events. AEDs are long- term treatments, and it is therefore im-
portant to fully understand any potential side effects.
This study aimed to evaluate whether individuals with 
epilepsy who are taking AEDs are at greater risk of experi-
encing a major cardiovascular event than individuals with-
out epilepsy. The study also examined whether the risk of 
clinically relevant cardiovascular outcomes differed in those 
treated with EIAEDs compared to NEIAEDs.
2 |  MATERIALS AND METHODS
2.1 | Data source
The study used data within the Secure Anonymised 
Information Linkage (SAIL) databank, which contains an-
onymized, routinely collected electronic health record (EHR) 
data from secondary care (hospitals; 100% population cover-
age) and primary care general practices (around 80% popula-
tion coverage) in Wales.16,17 The following SAIL data sources 
were used: Annual District Death Extract (ADDE), Patient 
Episode Database for Wales (PEDW), Welsh Demographic 
Service Dataset, and Welsh Longitudinal General Practice 
(WLGP) data. Read codes are the clinical coding system used 
in UK primary care systems to record diagnoses, prescrip-
tions, and symptoms.18 Version 2 Read codes were used to 
identify cases of epilepsy, comorbidities, and prescriptions 
within WLGP data. International Classification of Diseases, 
10th revision (ICD- 10) codes were used to identify comor-
bidities, cardiovascular events in hospital data (PEDW), and 
causes of death in death certificate data (ADDE). Lists of 
Read and ICD- 10 codes used are available from the corre-
sponding author upon request.
2.2 | Study design
An algorithm that has previously been shown to be 84% sen-
sitive and 98% specific was used to identify people with epi-
lepsy using primary care records.18 The algorithm requires 
cases to have an epilepsy diagnosis code as well as two sub-
sequent AED prescription codes within a 6- month window.18 
A cohort of people with a diagnosis of epilepsy between 
January 1, 2003 and December 31, 2017 and a start date for 
their first AED was identified, and any previous cardiovas-
cular disease was recorded at study entry. The study entry 
date was taken as the date of diagnosis of epilepsy. From this 
cohort, individuals were eligible for inclusion if they were at 
least 18 years of age at diagnosis, and had at least 6 months 
of available general practitioner (GP) data prior to and after 
their epilepsy diagnosis date. This criterion of 180 days of 
follow- up data meant that the latest epilepsy diagnosis date 
for inclusion in the study was June 30, 2017. We included 
K E Y W O R D S
cardiovascular risk, enzyme- inducing antiepileptic drugs
Key Points
• We studied 10 241 people with epilepsy who were 
prescribed antiepileptic drugs and 35 145 matched 
controls
• There was an increased risk of major cardiovascu-
lar events in the people with epilepsy
• There did not seem to be a difference when 
comparing enzyme- inducing and non- enzyme- 
inducing antiepileptic drugs
• Cardiovascular risk management is important in 
people with epilepsy
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only adults in this study, due to major cardiovascular events 
being relatively uncommon in children.
Individuals were followed to the end of the study 
(December 31, 2017) for the occurrence of a major cardio-
vascular event. If patients died during the study period (other 
than for cardiovascular causes) or moved to GP practices 
with no SAIL data coverage, they were censored.
Individuals were classified as being in the EIAED group 
if they had at least two prescriptions of phenytoin, pheno-
barbital, carbamazepine, methylphenobarbital, or primidone.
A control cohort was obtained from all eligible individu-
als in Wales without a diagnosis of epilepsy and matched on 
a 1:4 ratio based on age (week of birth), gender, Welsh Index 
of Multiple Deprivation (WIMD) 2011 version quintile, and 
year of entry into the study to cases with epilepsy. To allow 
a sufficient number of possible matches on year of entry into 
the study, controls were returned into the matching pool after 
meeting matching criteria, allowing matching with replace-
ment, where four controls were randomly selected from all 
possible matches for each case. Some individuals within the 
control cohort were therefore matched to more than one case.
2.3 | Assessment of a cardiovascular event
The primary outcome was the first occurrence of a major car-
diovascular event, after a diagnosis of epilepsy, within the 
study window. This was defined as a cardiac arrest, myo-
cardial infarction, stroke, ischemic heart disease, clinically 
significant arrhythmia (atrioventricular block, atrioven-
tricular dissociation, ventricular tachycardia, paroxysmal 
atrioventricular tachycardia, paroxysmal atrial tachycardia, 
paroxysmal tachycardia, and partial atrioventricular block), 
thromboembolism, onset of heart failure, or a cardiovascu-
lar death. Cardiovascular events were obtained from primary 
care records, hospital data, and death certificates, using pre-
viously validated case definitions.19 A cardiovascular death 
was defined as a death with any of the above events as the 
primary cause of death.
2.4 | Covariates
Baseline demographic and clinical characteristics were re-
corded to adjust the models for potential confounding factors. 
Deprivation was recorded using the WIMD 2011 version, 
which uses weighted scores from eight domains to form a 
score for small geographical areas or Lower Layer Super 
Output Areas (LSOAs). WIMD scores for each LSOA are 
then grouped into quintiles, with Quintile 1 being the most 
deprived and Quintile 5 being the least deprived. All vari-
ables were taken from the closest entry to the diagnosis date 
and identified with relevant diagnostic codes.
Smoking status was assigned following a previously vali-
dated method that uses primary care smoking status records 
to assign individuals into categories of smokers, ex- smokers, 
and never- smokers. The algorithm also addresses inconsis-
tencies and changes in smoking status over an individual's 
lifetime by using the first and last recorded date of a code 
in each category.20 Where the baseline smoking status was 
unavailable, the closest available recorded smoking status 
during the study period was used. If no smoking status was 
available, the participant was treated as a nonsmoker based 
on population estimates of smokers in Wales.21
Other conditions that may affect cardiovascular risk, such 
as diabetes, hypertension, and dyslipidemia were recorded, 
as well as previous cardiovascular events (cardiac arrest, 
myocardial infarction, stroke, ischemic heart disease, signif-
icant arrhythmia, thromboembolism, or onset of heart fail-
ure). Hypertension was recorded using diagnosis codes for 
hypertension, not prescriptions for antihypertensive agents. 
Medications prescribed within the study period that could 
affect cardiovascular risk (anticoagulants, antiplatelet drugs, 
and statins) were also recorded. Body mass index (BMI) was 
excluded from analysis due to high percentage of missing 
values (Table 1).
2.5 | Statistical analysis
Descriptive statistics were used to analyze the baseline demo-
graphic and clinical characteristics of the cohort and to com-
pare the characteristics of people with and without epilepsy.
Unadjusted and adjusted survival (time- to- event) models 
for time to a cardiovascular event were constructed. Cox pro-
portional hazard models were used for cardiovascular events 
for individuals in the case versus control groups. Survival 
models were adjusted for age, sex, WIMD quintile, smok-
ing status, coprescription of antiplatelets, anticoagulants, or 
statins, and previous diagnoses of hypertension, dyslipid-
emia, diabetes, thromboembolism, significant arrhythmia, 
ischemic heart disease, atrial fibrillation, cardiac arrest, myo-
cardial infarction, stroke, or heart failure. Time- to- event was 
defined as the time from the study entry date to either the 
first cardiovascular event or the time of censoring, whichever 
came first. Cases were censored on the first occurrence of 
moving to practices with no SAIL data coverage or noncar-
diovascular death. A logistic regression model was used to 
determine which of the baseline covariates had a significant 
impact on survival, with the occurrence or nonoccurrence 
of a cardiovascular event as the binary outcome variable. 
Adjusted Cox proportional hazard models were performed 
to calculate hazard ratios and estimate the risk of experienc-
ing a cardiovascular event between treatment groups. A pro-
portionality test was used to test for the proportional hazard 
assumption.
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Initial analyses compared differences between individu-
als in the epilepsy case and control groups. Cases were split 
into those treated with EIAEDs and NEIAEDs, and analysis 
was repeated to assess whether enzyme- inducing properties 





Control, n = 35 145, n 
(%) p
Age .451
18– 64 years 7335 (71.6%) 25 111 (71.4%)
65– 74 years 1304 (12.7%) 4375 (12.4%)
75+ years 1602 (15.6%) 5659 (16.1%)
Sex .640
Female 4897 (47.8%) 16 900 (48.1%)
Male 5344 (52.2%) 18 245 (51.9%)
BMI, kg/m2 <.001
Underweight, BMI < 20 205 (2.0%) 571 (1.6%)
Healthy weight, 
20 ≤ BMI < 25
2147 (21.0%) 7337 (20.9%)
Overweight, 
25 ≤ BMI < 30
1301 (12.7%) 4395 (12.5%)
Obese, BMI ≥ 30 724 (7.1%) 2139 (6.1%)
Unknown 5864 (57.3%) 20 703 (58.9%)
Smoking status <.001
Nonsmoker 593 (5.8%) 2439 (6.9%)
Ex- smoker 2318 (22.6%) 6455 (18.4%)
Current smoker 3903 (38.1%) 11 373 (32.4%)
Unknown status 3427 (33.5%) 14 878 (42.3%)
WIMD deprivation quintile .051
1, most deprived 2711 (26.5%) 9658 (27.5%)
2 2118 (20.7%) 7139 (20.3%)
3 2162 (21.1%) 7399 (21.1%)
4 1623 (15.8%) 5223 (14.9%)
5, least deprived 1627 (15.9%) 5726 (16.3%)
Diabetes 473 (4.6%) 1224 (3.5%) <.001
Hypertension 1291 (12.6%) 3825 (10.9%) <.001
Dyslipidemia 320 (3.1%) 9221 (2.6%) .007
Prior thromboembolism 5 (<.1%) 25 (.1%) .579
Prior arrhythmia 16 (.2%) 65 (.2%) .636
Prior cardiac arrest 8 (.1%) 16 (<.1%) .309
Prior atrial fibrillation 152 (1.5%) 386 (1.1%) .002
Prior ischemic heart disease 169 (1.7%) 507 (1.4%) .139
Prior myocardial infarction 129 (1.3%) 391 (1.1%) .239
Prior heart failure 73 (.7%) 190 (.5%) .052
Prior stroke 383 (3.7%) 367 (1.0%) <.001
Antiplatelet coprescription 3252 (31.8%) 7928 (22.6%) <.001
Anticoagulant coprescription 898 (8.8%) 2521 (7.2%) <.001
Statin coprescription 3489 (34.1%) 9925 (28.2%) <.001
Note: Numbers in parentheses show value as a percentage of the entire cohort.
Abbreviations: BMI, body mass index; WIMD, Welsh Index of Multiple Deprivation.
T A B L E  1  Baseline characteristics of 
epilepsy (case) and matched control cohorts
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Propensity score estimates were used to predict the proba-
bility of being prescribed either an EIAED or NEIAED, and 
then data were matched based on the estimated propensity 
score to produce a balanced dataset using nearest neighbor 
matching. A paired t- test was performed on matched data to 
compare the two treatment groups. A p- value of <.05 was set 
to indicate statistical significance. R Version 3.5.3 was used for 
statistical analysis.22 The R packages survminer and survival 
were used for survival analysis, and ggplot2 to plot graphs.
2.6 | Ethics
Written informed consent was not required for this study, 
as it used anonymized routinely collected data. All studies 
using SAIL data need independent Information Governance 
Review Panel (IGRP) approval. This study obtained IGRP 
approval reference 0758. STROBE (Strengthening the 
Reporting of Observational Studies in Epidemiology) guide-
lines for cohort, case– control, and cross- sectional studies 
have been followed with respect to reporting observational 
research.23
2.7 | Data availability statement
Linked pseudonymized patient data were used in this study. 
Under SAIL governance, patient- level data are only available 
on the SAIL Databank safe research platform. All proposals 
to use SAIL data are subject to review by an independent 
IGRP. Before any data can be accessed, approval must be 
given by the IGRP. The IGRP gives careful consideration to 
each project to ensure proper and appropriate use of SAIL 
data. When access has been approved, it is gained through 
a privacy- protecting safe haven and remote access system 
referred to as the SAIL Gateway. SAIL has established an 
application process to be followed by anyone who would like 
to access data via SAIL www.saild ataba nk.com/appli catio n- 
process. This study has been approved by the IGRP as project 
0758.
3 |  RESULTS
3.1 | Case and control cohorts
From a group of 26 351 individuals with a diagnosis of epi-
lepsy, an epilepsy (case) cohort of 10 241 was obtained after 
applying inclusion criteria (Figure 1). Cases were matched 
to 40 964 controls, with 35 145 distinct people in the control 
cohort (5819 repeated matches).
The baseline clinical and demographic characteristics 
of the case and control cohorts can be seen in Table 1. In 
decreasing order, the most commonly prescribed NEIAEDs 
were sodium valproate, lamotrigine, levetiracetam, gabapen-
tin, and pregabalin. Similarly, carbamazepine, phenytoin, 
primidone, and phenobarbital were the most commonly pre-
scribed EIAEDs (Table S1). During a mean (±SD) of 6.05 
(±4.31) years of overall follow- up (62  000 person- years), 
2115 major cardiovascular events occurred in the case cohort 
F I G U R E  1  Flow diagram of cohort 
selection. AED, antiepileptic drug; SAIL, 
Secure Anonymised Information Linkage 
Databank
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(3.41 events per 100 person- years). In the control cohort, 
4457 events were observed during a mean of 7.15 (±4.39) 
years of follow- up (251  330 person- years; 1.77 events per 
100 person- years).
3.2 | Survival analysis for case versus 
control cohorts
The unadjusted and adjusted survival (time- to- event) models 
for time to a cardiovascular event for individuals in the case 
versus control groups can be seen in Figure 2. This model 
adjusted for age, sex, WIMD quintile, smoking status, co-
prescription of antiplatelets, anticoagulants, or statins, and 
previous diagnoses of hypertension, dyslipidemia, diabetes, 
thromboembolism, significant arrhythmia, ischemic heart 
disease, atrial fibrillation, cardiac arrest, myocardial infarc-
tion, stroke, or heart failure. The unadjusted Cox proportional 
hazard ratio for cardiovascular events in the case cohort was 
1.47 (95% confidence interval [CI] = 1.45– 1.50, p < .001), 
and the adjusted hazard ratio was 1.53 (95% CI 1.50– 1.55), 
p < .001. Adjusting additionally for the time- dependent co-
variates (antiplatelet and anticoagulant coprescription) gave 
a hazard ratio of 1.58 (95% CI = 1.51– 1.63, p < .001; Cox 
proportional hazard analysis).
3.3 | Survival analysis for EIAED versus 
NEIAED cohorts
There were 3180 individuals in the EIAED group (31.1% 
of cases) and 7061 in the NEIAED group (68.9% of cases). 
Individuals were placed in the EIAED treatment group  if 
they had at least two prescriptions of an EIAED. The baseline 
clinical and demographic characteristics are summarized in 
Table 2. During a mean (±SD) of 7.36 (± 4.47) years of over-
all follow- up (total of 21 666 person- years), 632 major car-
diovascular events occurred in the EIAED group (2.92 events 
per 100 person- years). In the NEIAED cohort, 1483 events 
were observed during a mean of 5.53 (±4.13) years (total of 
40 355 person- years; 3.67 events per 100 patient years).
The unadjusted and adjusted survival (time- to- event) 
models for cardiovascular events in the NEIAED versus the 
EIAED group can be seen in Figure 3. The model adjusted 
for age, sex, smoking status, total AED prescription time (the 
total length of time for which an individual was prescribed ei-
ther EIAEDs or NEIAEDs), a coprescription of antiplatelets, 
anticoagulants, or statins, or a previous diagnosis of hyper-
tension, dyslipidemia, diabetes, thromboembolism, signif-
icant arrhythmia, ischemic heart disease, atrial fibrillation, 
cardiac arrest, myocardial infarction, stroke, or heart failure. 
The unadjusted Cox proportional hazard ratio for cardiovas-
cular events in the NEIAED group compared to the EIAED 
group was 1.12 (95% CI = 1.04– 1.20, p = .004). The adjusted 
hazard ratio for cardiovascular events in the EIAED group 
compared to the NEIAED group was .95 (95% CI = .86– 
1.05, p = .300). There was no difference in cardiovascular 
events in the propensity- matched EIAED and NEIAD groups 
(point estimate = .019, 95% CI = .007– .044, p = .151).
4 |  DISCUSSION
In this study, 10 241 people with epilepsy who were taking 
AEDs had a higher risk of major cardiovascular events than a 
matched control cohort (adjusted hazard ratio = 1.58, 95% CI 
= 1.51– 1.63). There was no difference in the risk of cardio-
vascular events in people with epilepsy who were prescribed 
F I G U R E  2  Unadjusted and adjusted time- to- event models for case versus control cohorts. (A) Unadjusted survival (time- to- event) models 
to compare the time to a cardiovascular event for individuals in the two treatment groups. Time- to- event is defined as the time from the index 
date (date of diagnosis/study start date) to either the first cardiovascular event or the time of censoring, whichever came first. (B) Survival 
model adjusted for age, sex, smoking status, a coprescription of antiplatelets, anticoagulants, or statins, or a previous diagnosis of hypertension, 
dyslipidemia, diabetes, thromboembolism, significant arrhythmia, ischemic heart disease, atrial fibrillation, cardiac arrest, myocardial infarction, 
stroke, or heart failure
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Variable





18– 64 years 2451 (77.1%) 4884 (69.2%)
65– 74 years 396 (12.5%) 908 (12.9%)
75+ years 333 (10.5%) 1269 (18.0%)
Sex .303
Female 1496 (47.0%) 3401 (48.2%)
Male 1684 (53.0%) 3660 (51.8%)
BMI, kg/m2 .072
Underweight, BMI < 20 71 (2.2%) 134 (1.9%)
Healthy weight, 
20 ≤ BMI < 25
711 (22.4%) 1436 (20.3%)
Overweight, 
25 ≤ BMI < 30
412 (13%) 889 (12.6%)
Obese BMI ≥ 30 225 (7.1%) 499 (7.1%)
Unknown 1761 (55.4%) 4103 (58.1%)
Smoking status .010
Nonsmoker 183 (5.8%) 410 (5.8%)
Ex- smoker 658 (20.7%) 1660 (23.5%)
Current smoker 1267 (39.8%) 2636 (37.3%)
Unknown status 1072 (33.7%) 2355 (33.4%)
WIMD deprivation quintile .081
1, most deprived 830 (26.1%) 1881 (26.6%)
2 711 (22.4%) 1407 (19.9%)
3 664 (20.9%) 1498 (21.2%)
4 488 (15.3%) 1145 (16.1%)
5, least deprived 487 (15.3%) 1140 (16.1%)
Diabetes 129 (4.1%) 344 (4.9%) .077
Hypertension 351 (11.0%) 940 (13.3%) .001
Dyslipidemia 109 (3.4%) 211 (3.0%) .262
Prior thromboembolism <5 (<.1%) <5 (<.1%) .360
Prior arrhythmia <5 (<.1%) 14 (.2%) .182
Prior cardiac arrest <5 (<.1%) 6 (.1%) 1.000
Prior atrial fibrillation 39 (1.2%) 113 (1.6%) .174
Prior ischemic heart disease 50 (1.6%) 119 (1.7%) .740
Prior myocardial infarction 42 (1.3%) 87 (1.2%) .782
Prior heart failure 21 (.7%) 52 (.7%) .767
Prior stroke 134 (4.2%) 249 (3.5%) .101
Antiplatelet coprescription 981 (30.8%) 2271 (32.2%) .194
Anticoagulant coprescription 245 (7.7%) 653 (9.2%) .012
Statin coprescription 1147 (36.1%) 2342 (33.2%) .004
Note: Numbers in parentheses show value as a percentage of the entire cohort.
Abbreviations: BMI, body mass index; EIAED, enzyme- inducing antiepileptic drug; NEIAED, non- enzyme- 
inducing antiepileptic drug; WIMD, Welsh Index of Multiple Deprivation.
T A B L E  2  Baseline characteristics of 
EIAED and NEIAED treatment groups
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EIAEDs compared to NEIAEDs (adjusted hazard ratio = .95, 
95% CI = .86– 1.05).
4.1 | Major cardiovascular events in 
case and control cohorts
Previous studies have found an increased risk of stroke and 
myocardial infarction for people with epilepsy.24– 26 A recent 
systematic review found hazard ratios of 1.09– 2.85 for stroke 
and 1.09– 1.48 for myocardial infarction.26 It is possible that 
people with epilepsy may have reduced physical activity, dif-
ferent diets, or increased rates of obesity. Stress, anxiety, and 
depression are also common with epilepsy and could impact 
other cardiovascular risk factors.27 These lifestyle- related 
cardiovascular risk factors were not measured in this study 
due to the inconsistency of documentation in routinely col-
lected data. Another reason may be that epilepsy caused by 
atherosclerotic cerebrovascular disease may precede major 
cardiovascular events caused by the atherosclerotic cardio-
vascular disease. This may be independent of AED use, or 
AEDs may promote risk. Cardiac syncope can occasionally 
be misdiagnosed as epilepsy, with these cases having an in-
creased risk of significant arrhythmias.28 AEDs can rarely 
cause significant arrhythmias, which could increase risk of 
significant cardiovascular events and death.29,30
Less favorable lipid profiles have previously been noted 
in people with epilepsy.31,32 Although this has been mostly 
found in relation to EIAEDs, it is possible that NEIAEDs may 
also increase metabolic cardiovascular risk. For example, so-
dium valproate is commonly prescribed and is known to in-
crease body weight and may increase the risk of developing 
metabolic syndrome.33,34 Epileptic seizures themselves may 
have a negative effect on the cardiovascular system via 
seizure- induced hypoxia, sympathetic activation, or ictal ar-
rhythmias.35 Seizure frequency and AED doses, which also 
may be associated with cardiovascular risk, cannot currently 
be measured accurately in the routinely collected data within 
the SAIL Databank.
Increasing age, male sex, smoking, deprivation, diabe-
tes, dyslipidemia, and previous cardiovascular events (isch-
emic heart disease, heart failure, atrial fibrillation, stroke, 
and thromboembolism) were significantly associated with 
major cardiovascular events (Table 3). Antiplatelets, anti-
coagulants, and statins were also significantly associated 
with major cardiovascular events. We hypothesize that these 
medications are markers for an increased underlying cardio-
vascular risk, given that they are normally prescribed to in-
dividuals with an increased underlying cardiovascular risk 
profile or for secondary prevention. Other variables were 
not significantly associated with altered risk of major car-
diovascular events.
4.2 | Major cardiovascular events in the 
EIAED and NEIAED cohorts
This study did not find a significant difference in survival 
between the EIAED and NEIAED groups when adjusting 
for covariates. Previous studies have suggested a link be-
tween EIAEDs and increased serum levels of total choles-
terol, high- density lipoprotein cholesterol (HDL- C), and 
non- HDL- C compared with the use of NEIAEDs or no 
AEDs.8,12 A recent study found a higher rate of diagnosis 
F I G U R E  3  Unadjusted and adjusted time- to- event survival curves for enzyme- inducing antiepileptic drug (EIAED) and non- enzyme- 
inducing antiepileptic drug (NEIAED) treatment groups. (A) Unadjusted survival (time- to- event) models to compare the time to a cardiovascular 
event for individuals in the two treatment groups. Time- to- event is defined as the time from the index date (date of diagnosis/study start date) to 
either the first cardiovascular event or the time of censoring, whichever came first. (B) Survival model adjusted for age, sex, smoking status, total 
antiepileptic drug prescription time (the total length of time for which an individual was prescribed either EIAEDs or NEIAEDs), a coprescription 
of antiplatelets, anticoagulants, or statins, or a previous diagnosis of hypertension, dyslipidemia, diabetes, thromboembolism, significant 
arrhythmia, ischemic heart disease, atrial fibrillation, cardiac arrest, myocardial infarction, stroke, or heart failure
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ratio 95% CI p
Case (epilepsy) vs. control group
Group Control (reference) 1.0
Epilepsy 1.58 1.51– 1.63 <.001
Age Age 18 years (reference) 1.0
Each additional year 1.06 1.05– 1.06 <.001
Sex Male (reference) 1.0
Female .82 .78– .87 <.001
Smoker Nonsmoker (reference) 1.0
Smoker 1.09 1.03– 1.15 <.001
Deprivation WIMD quintile 1 (reference, most 
deprived)
1.0
Each additional quintile .94 .92– .95 <.001
Coprescriptions Antiplatelet 2.74 2.56– 2.92 <.001
Anticoagulants 1.78 1.68– 1.88 <.001
Statins 1.50 1.41– 1.59 <.001
Comorbidities Diabetes 1.14 1.05– 1.23 .002
Dyslipidemia .84 .76– .93 <.001
Hypertension 1.00 .95– 1.07 .801
Previous CV events Ischemic heart disease 1.18 1.05– 1.34 .008
Heart failure 1.86 1.60– 2.16 <.001
Atrial fibrillation 1.24 1.10– 1.40 <.001
Myocardial infarction 1.10 .96– 1.27 .171
Stroke 1.91 1.63– 2.23 <.001
Thromboembolism 2.09 1.30– 3.37 .002
Arrhythmia .75 .47– 1.17 .203
Cardiac arrest 1.33 .79– 2.26 .287
EIAED vs. NEIAED group
Group NEIAED (reference) 1.0
EIAED .95 .86– 1.05 .300
Age Age 18 years (reference) 1.0
Each additional year 1.04 1.04– 1.04 <.001
Sex Male (reference) 1.0
Female .84 .77– .91 <.001
Smoker Nonsmoker (reference) 1.0
Smoker 1.18 1.08– 1.30 .001
Deprivation WIMD quintile 1 (reference, most 
deprived)
1.0
Each additional quintile .97 .94– 1.00 .087
Coprescriptions Antiplatelet 2.38 2.13– 2.67 <.001
Anticoagulants 1.92 1.73– 2.13 <.001
Statins 1.63 1.47– 1.81 <.001
Comorbidities Diabetes 1.15 1.00– 1.33 .054
Dyslipidemia .83 .70– .99 .040
Hypertension 1.13 1.03– 1.25 .014
(Continues)
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of hyperlipidemia in a cohort started on EIAEDs compared 
with NEIAEDs.36
Other studies have addressed the risk of cardiovascular 
events, according to AED enzymatic properties, for people 
prescribed AEDs for epilepsy and other indications.35,36 
These studies found no significant difference in stroke risk 
in those prescribed EIAEDs and NEIAEDs.37,38 One study 
noted a slight increase in myocardial infarction risk in those 
prescribed EIAEDs, a risk difference of 1.39/1000.38 It is pos-
sible that the effect of EIAEDs on lipid profiles is dominated 
by a considerable risk from epilepsy itself, independent of 
any differential metabolic effect of epilepsy medication type 
on cardiovascular risk. It would seem therefore that although 
EIAEDs are associated with metabolic changes related to vas-
cular risk, this does not necessarily lead to an increased risk 
of major cardiovascular events when compared to NEIAEDs.
The NEIAED group had a slightly higher rate of cardio-
vascular events in the unadjusted analysis when compared to 
the EIAED (unadjusted hazard ratio = 1.12, 95% CI = 1.04– 
1.20, p = .004). This could be because they seem to be pre-
scribed to a slightly older population; 18% of prescriptions 
in the older than 75 years group are for NEIAED compared 
to 10.5% for EIAED. Clinicians may preferentially select 
NEIAED for older frail people to minimize adverse effects. 
This difference does not remain in the adjusted analysis 
where age is accounted for. Sodium valproate was the most 
commonly prescribed NEIAED and is associated with weight 
gain and other metabolic effects that may increase the risk of 
cardiovascular events.33,34
Increasing age, male sex, smoking, hypertension, and pre-
vious stroke were significantly associated with major cardio-
vascular events (Table 3). As in the epilepsy versus control 
analysis, antiplatelets, anticoagulants, and statins were also 
significantly associated with major cardiovascular events 
(see above for our explanation). Other variables were not sig-
nificantly associated with increased risk of major cardiovas-
cular events.
4.3 | Study strengths
This study includes a large number of individuals (10  241 
cases, 35 145 controls), followed up for a long period (study 
window of 15 years, mean follow- up of 6.90 years, 313 330 
person- years), with documentation of a large number (6572) 
of cardiovascular events. Population- level routinely col-
lected data were used, which reduces recruitment bias and 
enables detailed capture and adjustment for cardiovascular 
covariates and events. EIAED or NEIAED prescription du-
ration was accounted for in the analysis. Using population- 
level data enabled the control cohort to be matched on year of 
entry into the study, helping to account for changes in health 
care provision with time.
Previous studies have limited their analysis to stroke 
and myocardial infarction risk, whereas this study also con-
siders other significant cardiovascular events. This study 
has also taken into account a wider range of vascular risk 
factors than other studies that do not consider as many po-
tential confounding factors such as age, sex, and relevant 
coprescriptions.5,25
4.4 | Study limitations
Routinely collected EHR data are not primarily collected for 
research purposes, can be incomplete, and may contain inac-
curate diagnosis codes. The method that was used to identify 
epilepsy cases within the SAIL Databank has been previ-
ously estimated to have a sensitivity of 84% and a specificity 
of 98%.18
Not all cardiovascular risk factors were included in this 
analysis; for example, physical activity levels, family history, 
and diet were not included, as they are difficult to obtain 
accurately from routinely collected data. BMI was excluded 
from analysis due to high percentage of missing values. 
Smoking was included in the analysis, but there was a high 
Variable Group
Hazard 
ratio 95% CI p
Previous CV events Ischemic heart disease 1.11 .87– 1.41 .396
Heart failure 1.34 .99– 1.82 .056
Atrial fibrillation 1.16 .93– 1.44 .187
Myocardial infarction 1.03 .80– 1.34 .805
Stroke 2.22 1.88– 2.63 <.001
Thromboembolism .70 .10– 4.98 .720
Arrhythmia 1.09 .45– 2.63 .846
Cardiac arrest 1.08 .40– 2.94 .870
Hazard ratios in bold are significantly different to 1 (p < .05).
Abbreviations: CI, confidence interval; CV, cardiovascular; EIAED, enzyme- inducing antiepileptic drug; NEIAED, non- enzyme- inducing antiepileptic drug; WIMD, 
Welsh Index of Multiple Deprivation.
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level of missing data on smoking status (around one third of 
the epilepsy cohort), which was assigned nonsmoker status 
based on estimates of populations who smoke. Epilepsy fac-
tors such as severity, syndrome, and seizure frequency that 
may have an influence on cardiovascular outcomes were not 
included in this study, as they are not accurately recorded 
in the routinely collected EHR data used in this study. The 
group of people prescribed NEIADs were older than the 
group of people prescribed EIADs, and although we did ad-
just for age, this might be an important factor. A minimum 
of 6 months of data coverage prior to and after epilepsy di-
agnosis was specified as an inclusion criterion, to ensure that 
epilepsy diagnoses were new. This might not have been long 
enough to exclude all prevalent cases; however, 95% of the 
cases had at least 2 years of data prior to their diagnosis, and 
the mean length of data prior to diagnosis was 3.5 years.
Only people with epilepsy who were taking AEDs were 
included, as it has been previously found that this gives more 
accurate epilepsy case ascertainment in routinely collected 
data.18 It therefore cannot be said whether it is the epilepsy, 
the AEDs, or both that increase cardiovascular risk. Also, 
the AED dosage was not available to include in the analy-
sis. The mean length of follow- up was 6 years in this study. 
Cardiovascular disease can potentially take longer than this 
to develop, and so cardiovascular events that occurred after 
a longer time period will not have been included.
4.5 | Impact
This study demonstrates that adults with epilepsy who are 
taking AEDs are more likely to experience major cardio-
vascular events than the general population after account-
ing for relevant comorbidities and treatments. It is therefore 
important that health care professionals and people with epi-
lepsy prioritize identification and treatment of cardiovascu-
lar disease and its risk factors. For example, making dietary 
changes, increasing physical activity levels, stopping smok-
ing, and treating hypertension and hypercholesterolemia can 
all reduce the risk of developing cardiovascular events.
Previous studies have demonstrated that EIAEDs could 
increase cholesterol and lipid levels. However, this study 
does not support an increase in major cardiovascular events 
at a population level. This is important when changes from 
EIAEDs to NEIAEDs are being considered, as the risks of 
breakthrough seizures may not be outweighed by the benefits 
of switching from EIAEDs to NEIAEDs.
5 |  Conclusions
Overall, this study suggests that individuals with epilepsy 
who are taking AEDs are at a significantly greater risk of 
experiencing major cardiovascular events than the general 
population. This is corroborated by other studies, highlight-
ing the need for rigorous management of cardiovascular risk 
in people with epilepsy who have been prescribed AEDs.
Our study has not observed any significant difference in 
the rates of major cardiovascular events in those prescribed 
EIAEDs and NEIAEDs, which merits further investigation 
and may have important implications for treatment selection 
in clinical practice.
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